Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials

* CEPI backs effort with up to $8.5 million in funding * Hilleman aims to make finished doses for early-stage trials using IAVI starting material * Partners would transfer technology to a large-scale

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)